SAR447537
Phase 2Small molecule
SanofiSAR447537 is one of 40 small molecule programs targeting Emphysema. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Emphysema
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Pulmicort
SSalix
Approved
Serevent
GGlaxo Dba Glaxosmithkline
Approved
Foradil
ViatrisApproved
Advil
KKenvue Brands
Approved
Alpha1-Proteinase Inhibitor
CSL BehringApproved
Pulmicort Pmdi HFA
AstraZenecaApproved
Budesonide/formoterol
AstraZenecaPhase 3
Benlysta
GGlaxo Dba Glaxosmithkline
Phase 2
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SAR447537. EMBL-EBI & Wellcome Sanger Institute.
- [4]